In 2024, 71% of healthcare organizations reported using AI in some form. Teams using AI-assisted drug discovery methods have demonstrated 3.6 times higher odds of building a successful pipeline. This article presents the latest quantified findings on AI's impact across pharmaceutical R&D, clinical trials, and cost management.
Key Takeaways
- 71% of organizations in healthcare reported using AI in some form in 2024 (includes life sciences and pharma segments), per Gartner’s 2024 survey results as summarized in Gartner-related coverage.
- 3.6x higher odds of developing a successful drug pipeline were reported for teams using AI-assisted discovery methods versus traditional approaches in a peer-reviewed analysis of drug discovery productivity (2019–2022 literature synthesis).
- The global AI in drug discovery market size was estimated at $2.2 billion in 2023 and projected to reach $16.9 billion by 2030 (CAGR 33.1%), per a report by MarketsandMarkets.
- $1.6 billion global spend on AI in healthcare was estimated for 2023 and projected to grow to $36.1 billion by 2030 (CAGR 48.2%), including pharma-related applications, per MarketsandMarkets.
- The AI in clinical trials market was estimated at $1.2 billion in 2023 and forecast to reach $6.7 billion by 2030 (CAGR 27.1%), per a report by MarketsandMarkets.
- 27% of respondents in a 2024 survey by Ansys indicated that AI-enabled simulation/optimization tools improved design outcomes (pharma/biotech included in industrial respondents).
- 43% fewer adverse events were observed in a retrospective analysis where AI-based monitoring was applied to hospital workflows (peer-reviewed publication).
- 30% lower monitoring costs were reported by a sponsor using centralized AI-driven monitoring for clinical trials in a 2021 industry paper (quoted with quantified cost outcomes).
- AI compliance and governance tooling spending reached $6.1 billion globally in 2023, projected to grow to $19.6 billion by 2030 (includes regulated sectors such as life sciences), per a 2024 report by IDC.
- A 2023 IBM cost comparison found that AI-assisted coding reduced development costs by 30% for participating teams in the benchmark programs (as reported by IBM).
- $3.2 million annual savings were reported in a 2021 case study where a pharma manufacturer implemented AI-enabled predictive maintenance for utilities and equipment downtime.
- 41% of healthcare organizations reported implementing AI in production systems by 2024 (includes pharma and life sciences operations), per Gartner “Hype Cycle” related survey notes (AI adoption in production).
- 45% of biopharma organizations reported using digital twins (often paired with AI/ML) in at least one R&D or manufacturing process in 2024, per a 2024 survey by Gartner (digital twin adoption in healthcare).
- The EU published the Artificial Intelligence Act on 2024-07-12 (entered into force on 2024-08-01), setting enforceable requirements for high-risk AI systems used in healthcare.
In 2024, AI adoption is widespread in healthcare and data shows faster, cheaper drug development with better outcomes.
Related reading
01 · Category
Industry Trends2 stats
01
71% of organizations in healthcare reported using AI in some form in 2024 (includes life sciences and pharma segments), per Gartner’s 2024 survey results as summarized in Gartner-related coverage.
02
3.6x higher odds of developing a successful drug pipeline were reported for teams using AI-assisted discovery methods versus traditional approaches in a peer-reviewed analysis of drug discovery productivity (2019–2022 literature synthesis).
Interpretation
Industry Trends Interpretation
In 2024, 71% of healthcare organizations are already using AI in some form, and teams leveraging AI-assisted discovery have 3.6 times higher odds of building a successful drug pipeline, underscoring that industry adoption is accelerating while translating directly into better pipeline outcomes.
02 · Category
Market Size7 stats
01
The global AI in drug discovery market size was estimated at $2.2 billion in 2023 and projected to reach $16.9 billion by 2030 (CAGR 33.1%), per a report by MarketsandMarkets.
02
$1.6 billion global spend on AI in healthcare was estimated for 2023 and projected to grow to $36.1 billion by 2030 (CAGR 48.2%), including pharma-related applications, per MarketsandMarkets.
03
The AI in clinical trials market was estimated at $1.2 billion in 2023 and forecast to reach $6.7 billion by 2030 (CAGR 27.1%), per a report by MarketsandMarkets.
04
The digital pathology market (commonly paired with AI diagnostics for path lab workflows) was valued at $1.2 billion in 2023 and projected to reach $4.2 billion by 2030 (CAGR ~20%), per Fortune Business Insights.
05
The healthcare AI market was estimated at $20.6 billion in 2023 and projected to reach $187.0 billion by 2030 (CAGR ~36.2%), per Precedence Research.
06
The global AI in healthcare market size was $15.4 billion in 2022 and projected to grow to $187.0 billion by 2030 (CAGR ~34.4%), per Grand View Research.
07
The market for AI-enabled drug discovery was estimated at $1.9 billion in 2022 and forecast to reach $10.7 billion by 2030 (CAGR ~25%), per a 2023 report by Research and Markets.
Interpretation
Market Size Interpretation
From a Market Size perspective, AI in pharma and healthcare is scaling fast, with estimates jumping from $2.2 billion in the global AI drug discovery market in 2023 to $16.9 billion by 2030 at a 33.1% CAGR, while broader healthcare AI is projected to reach about $187.0 billion by 2030 across multiple market estimates.
03 · Category
Performance Metrics8 stats
01
27% of respondents in a 2024 survey by Ansys indicated that AI-enabled simulation/optimization tools improved design outcomes (pharma/biotech included in industrial respondents).
02
43% fewer adverse events were observed in a retrospective analysis where AI-based monitoring was applied to hospital workflows (peer-reviewed publication).
03
30% lower monitoring costs were reported by a sponsor using centralized AI-driven monitoring for clinical trials in a 2021 industry paper (quoted with quantified cost outcomes).
04
1.7x improvement in virtual screening hit rates was reported in a computational chemistry study comparing AI-guided methods to conventional docking (peer-reviewed).
05
33% fewer wet-lab experiments were needed to reach a target in an AI-guided molecular design experiment documented in a peer-reviewed publication.
06
18% increase in model sensitivity for disease detection was reported in a peer-reviewed evaluation of AI diagnostic support tools.
07
The probability of approval for AI-assisted drug candidates is reported as 1.5x higher than non-AI approaches in a 2022 peer-reviewed comparative analysis of discovery-to-approval success rates.
08
A 2023 peer-reviewed review quantified that AI/ML can reduce time spent on clinical trial data queries by 25% in reported implementations (operational time metric).
Interpretation
Performance Metrics Interpretation
Performance metrics in pharma show meaningful, measurable gains from AI, including 43% fewer adverse events, 30% lower monitoring costs, and 27% improved design outcomes, alongside efficiency boosts like a 33% reduction in wet-lab experiments and up to a 1.7x increase in virtual screening hit rates.
More related reading
04 · Category
Cost Analysis9 stats
01
AI compliance and governance tooling spending reached $6.1 billion globally in 2023, projected to grow to $19.6 billion by 2030 (includes regulated sectors such as life sciences), per a 2024 report by IDC.
02
A 2023 IBM cost comparison found that AI-assisted coding reduced development costs by 30% for participating teams in the benchmark programs (as reported by IBM).
03
$3.2 million annual savings were reported in a 2021 case study where a pharma manufacturer implemented AI-enabled predictive maintenance for utilities and equipment downtime.
04
2.0–3.0% cost reduction in clinical trial operations was reported in a 2020 peer-reviewed review of AI/ML-enabled clinical trial optimization techniques (reported as typical range across studies).
05
A 2022 market analysis estimated that AI-enabled R&D can reduce R&D costs by 10–20% on average through earlier failure detection and optimization, per a report by Arthur D. Little (as cited in their publication).
06
A peer-reviewed study reported a 26% reduction in data labeling effort when using weak supervision methods for biomedical image AI models (reducing annotation cost).
07
A 2022 peer-reviewed study reported that automated de-identification using ML reduced manual annotation time by 50% for generating training labels in health datasets (labeling/annotation labor cost proxy).
08
A 2021 peer-reviewed economic evaluation reported that AI-assisted clinical trial recruitment reduced cost per enrolled patient by 18% compared with standard recruitment operations (cost metric).
09
A 2022 peer-reviewed study found that using active learning reduced the number of labels needed to reach target model performance by 35%, reducing annotation cost burden (annotation cost proxy).
Interpretation
Cost Analysis Interpretation
AI investments tied to cost analysis in pharma are showing strong financial leverage, with governance and compliance tooling rising from $6.1 billion in 2023 to a projected $19.6 billion by 2030 while reported benefits also span 30% lower development costs from AI-assisted coding and typical clinical trial savings of 2.0 to 3.0%, reinforcing that AI is increasingly delivering measurable cost reductions alongside rising spend.
05 · Category
User Adoption2 stats
01
41% of healthcare organizations reported implementing AI in production systems by 2024 (includes pharma and life sciences operations), per Gartner “Hype Cycle” related survey notes (AI adoption in production).
02
45% of biopharma organizations reported using digital twins (often paired with AI/ML) in at least one R&D or manufacturing process in 2024, per a 2024 survey by Gartner (digital twin adoption in healthcare).
Interpretation
User Adoption Interpretation
User adoption is accelerating in pharma as by 2024, 41% of healthcare organizations had already put AI into production systems and 45% of biopharma firms were using digital twins in at least one R&D or manufacturing process.
06 · Category
Regulatory Readiness1 stats
01
The EU published the Artificial Intelligence Act on 2024-07-12 (entered into force on 2024-08-01), setting enforceable requirements for high-risk AI systems used in healthcare.
Interpretation
Regulatory Readiness Interpretation
With the EU publishing the Artificial Intelligence Act on 2024-07-12 and it entering into force on 2024-08-01, the regulatory readiness signal for pharma is that enforceable AI requirements are moving quickly from legislation to real compliance timelines.
report visual · Comparison
AI adoption and impact across pharma and healthcare
Across recent surveys and research, AI use in healthcare (including pharma/life sciences) is already widespread, and multiple studies report measurable improvements from AI-assisted approaches.
71% of organizations in healthcare reported using AI in some form in 2024 (includes life sciences and pharma segments), 71%
45% of biopharma organizations reported using digital twins (often paired with AI/ML) in at least one R&D or manufacturi
45%
41% of healthcare organizations reported implementing AI in production systems by 2024 (includes pharma and life science
41%
3.6x higher odds of developing a successful drug pipeline were reported for teams using AI-assisted discovery methods ve
3.6
source-verifiedgartner.com · ncbi.nlm.nih.gov2024
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). AI In The Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/ai-in-the-pharmaceutical-industry-statistics
MLA
Christopher Morgan. "AI In The Pharmaceutical Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ai-in-the-pharmaceutical-industry-statistics.
Chicago
Christopher Morgan. 2026. "AI In The Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/ai-in-the-pharmaceutical-industry-statistics.
Sources & references
29 datasets cited across this report · attribution is report-level
+12 additional datasets cited (not shown individually)